Inhibiting T-Cell proliferation
AssigneeBioCryst Pharmaceuticals, Inc.
InventorsShanta Bantia, John A. Montgomery, Philip E. Morris, Jr.
Life of this patent
Estimating the term…
Abstract
T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2′-deoxyguanosine and/or prodrugs thereof; and certain PNP inhibitors.
Claims13
A process for enhancing the inhibition of T-cell proliferation in a mammalian host in need thereof by administering to said boat an enhanced effective amount of 2′-deoxyguanosine, and at least one PNP inhibitor having a Ki of 500 picomolar or less and wherein said at least one PNP inhibitor comprises at least one compound represented by the formula:
- wherein A is CH or N;
- B is selected from the group consisting of OH, NH2, NHR, H or halogen;
- D is selected from the group consisting of OH, NH2, NHR, H, halogen or SCH3;
- R is an optionally substituted alkyl, aralkyl or aryl group;
- and X and Y are independently selected from the group consisting of H, OH or halogen except that when one of X and Y is hydroxy or halogen, the other is hydrogen;
- and Z is OH or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group;
- or a tautomer thereof;
- or a pharmaceutically acceptable salt thereof;
- or an ester thereof.
A process for enhancing the inhibition of T-cell proliferation in a mammalian host in need thereof by orally administering to said host an enhanced effective amount of 2′-deoxyguanosine and administering to said bust an effective amount of (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;
- and wherein the T-cell proliferation is sensitive to the above combination.
Dependencies are inferred from the claim text.